Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 5:33 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 63 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Opioid Induced Constipation Clear all

Conditions: Low Back Pain
Interventions: Oxycodone/Naloxone controlled-release, Oxycodone HCl controlled-release, Placebo; Drug
Lead sponsor: Purdue Pharma LP; Industry
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 149
States / cities: Alabaster, Alabama • Birmingham, Alabama • Foley, Alabama + 114 more

Conditions: Opioid-induced Constipation
Interventions: Methylnaltrexone bromide, Placebo; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Tarrytown, New York

Conditions: Constipation
Interventions: Lubiprostone, Senna; Drug
Lead sponsor: Shirley Ryan AbilityLab; Other
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Constipation
Interventions: Tegaserod; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 670 participants
Timeline: 2006 – 2007
U.S. locations: 59
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 52 more

Conditions: Opioid-induced Constipation
Interventions: Methylnaltrexone; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Tarrytown, New York

Conditions: Bowel Dysfunction, Constipation
Interventions: Alvimopan, Placebo; Drug
Lead sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years and older
Enrollment: 805 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 143
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 120 more

Conditions: OIC
Interventions: TD-1211 IV [C14], TD-1211 PO [C14]; Drug
Lead sponsor: Glycyx Therapeutics; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Opioid-Induced Bowel Dysfunction
Interventions: Lubiprostone, Placebo; Drug
Lead sponsor: Sucampo Pharma Americas, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 439 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 94
States / cities: Birmingham, Alabama • Hueytown, Alabama • Mobile, Alabama + 79 more

Conditions: Constipation, Analgesia
Interventions: Naloxone and Docusate; Drug
Lead sponsor: CAMC Health System; Other
Eligibility: 18 Years to 65 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Charleston, West Virginia

Conditions: Opioid-induced Constipation
Interventions: Naldemedine, Placebo; Drug
Lead sponsor: Shionogi; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 547 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 37
States / cities: Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 34 more

Conditions: OIC
Interventions: Relistor Injectable Product, Docusate Calcium, Bisacodyl, Milk of magnesia, Magnesium citrate, Senna, Enema; Drug
Lead sponsor: Methodist Health System; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Opioid Induced Bowel Dysfunction
Interventions: Naldemedine, Placebo; Drug
Lead sponsor: Shionogi; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Opioid-induced Constipation (OIC)
Interventions: TD-1211, Placebo; Drug
Lead sponsor: Glycyx Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Constipation
Interventions: naloxegol; Drug
Lead sponsor: Joseph Ma; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Opioid-induced Constipation
Interventions: Methylnaltrexone Bromide, Placebo-Normal Saline; Drug
Lead sponsor: St. John Health System, Michigan; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Southfield, Michigan

Conditions: Opioid-induced Bowel Dysfunction
Interventions: Lubiprostone, Placebo; Drug
Lead sponsor: Sucampo Pharma Americas, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 439 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 115
States / cities: Athens, Alabama • Birmingham, Alabama • Foley, Alabama + 89 more

Conditions: Constipation
Interventions: N-methylnaltrexone bromide (MOA-728), placebo; Drug · Other
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 41
States / cities: Mobile, Alabama • Litchfield Park, Arizona • Tucson, Arizona + 36 more

Conditions: Healthy, Opioid-induced Constipation
Interventions: TD-1211, Placebo; Drug
Lead sponsor: Glycyx Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 3
States / cities: Pasadena, California • San Antonio, Texas • Salt Lake City, Utah

Conditions: Opioid-Induced Constipation (OIC)
Interventions: NKTR-118, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 84 Years
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 68
States / cities: Mobile, Alabama • Pell City, Alabama • Mesa, Arizona + 65 more

Conditions: Constipation, Impaction, and Bowel Obstruction, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: naloxone hydrochloride; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years to 120 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Patients With Opioid Induced Constipation
Interventions: Not listed
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 520 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 24
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 21 more

Conditions: Constipation, Constipation Drug Induced
Interventions: Naloxegol 25 MG, Placebo pill; Drug · Other
Lead sponsor: TriHealth Inc.; Other
Eligibility: 18 Years and older
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Bowel Dysfunction
Interventions: SC MNTX; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 1
States / cities: Tarrytown, New York

Conditions: Opioid-Induced Constipation
Interventions: Methylnaltrexone bromide; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 26
States / cities: Mobile, Alabama • Laguna Hills, California • Lancaster, California + 20 more

Search by objective public record fields.

A Study of Oxycodone/Naloxone Controlled-release Tablets (OXN) to Assess Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain

Study of Subcutaneous Methylnaltrexone (MNTX) in the Treatment of Opioid-Induced Constipation During Rehabilitation After Orthopedic Procedures

Lubiprostone (Amitiza®) Vs. Standard Care in Opioid-induced Constipation After Surgery in Inpatient Rehabilitation

Efficacy and Safety of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain

Compassionate Use Study of Methylnaltrexone

Long-Term Safety Evaluation Of Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain

TD-1211 IV/Oral Mass Balance Study

Opioid-induced Bowel Dysfunction: Pivotal Assessment of Lubiprostone

Enteral Naloxone Versus a Traditional Bowel Regimen for the Prevention of Opioid Induced Constipation in Trauma Patients

Efficacy and Safety of Naldemedine in the Treatment of Opioid-induced Constipation

RELISTOR's Effects on Opioid-Induced Constipation

Study to Evaluate the Safety and Efficacy of Naldemedine (S-297995) for the Treatment of Opioid-Induced Bowel Dysfunction in Subjects With Chronic Pain

A Study to Assess the Safety, Tolerability and Clinical Activity of TD-1211 in Patients With Opioid-Induced Constipation

Naloxegol in Cancer Opioid-Induced Constipation

Methylnaltrexone for Treatment of Opiate-Induced Constipation in the Intensive Care Unit

Opioid-induced Bowel Dysfunction (OBD) Pivotal Assessment of Lubiprostone (OPAL)

Study Evaluating Oral MOA-728 For The Treatment Of OIBD In Subjects With Chronic Non-Malignant Pain

A Multiple Dose Study of TD-1211 in Healthy Volunteers and Patients With Opioid-Induced Constipation

Assessment of Efficacy and Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation

Naloxone in Treating Constipation in Patients Who Are Receiving Opioids for Chronic Pain

Longitudinal Study of Patients With Opioid-Induced Constipation

Naloxegol and Opioid-induced Constipation

Methylnaltrexone in Patients With Opioid-Induced Bowel Dysfunction

Safety of Subcutaneous Methylnaltrexone for Opioid-Induced Constipation in Patients With Advanced Illness